It has been shown that use of Stockholm3 as an adjunct test to prostate-specific antigen (PSA) is effective in PC screening in large population-based trials and in real-world evidence, improving identification of curable clinically significant PC and reducing overdiagnosis of low-grade cancers [5], [6], [7], [8], [9]. Here, KLK3 is linked to cancer.